21 results
Thumbnail

D1.452 - Remission as a therapeutic goal in chronic rhinosinusitis with nasal polyps treated with Dupilumab: a multicenter real-world study

Thumbnail

D1.453 - Pregnancy in Eosinophilic Granulomatosis with Polyangiitis (EGPA): a case report and literature review

Thumbnail

D1.455 - Dupilumab Efficacy in Unified Airways Disease: Pooled Analysis of Patients With Chronic Rhinosinusitis With Nasal Polyps/Allergic Fungal Rhinosinusitis With Coexisting Asthma in Ph3/4 Clinical Trials

Thumbnail

D1.457 - Clinical and immune profile of newborns born to mothers with inflammatory diseases exposed to biological drugs during pregnancy

Thumbnail

D1.460 - Diagnostic Opportunities in Type 2 Inflammations - A Machine-Learning Approach: EAACI Task Force Update

Thumbnail

D1.461 - Dupilumab as a Steroid-Sparing Treatment Option for Pemphigus Vulgaris: A Case Series from a Tertiary Centre

Thumbnail

D1.463 - Real-World Transition from Reference Omalizumab to Biosimilar Omlyclo in Patients with Chronic Urticaria: A Single-Center Descriptive Study

Thumbnail

D1.451 - Adherence and persistence to biological treatments in patients with CRSwNP and comorbid asthma

Thumbnail

D1.456 - Integrated Analysis of Nemolizumab Immunogenicity Indicates No Effect on the Overall Benefit-Risk Profile of Nemolizumab in Patients with Atopic Dermatitis or with Prurigo Nodularis

Thumbnail

D3.440 - Long-Term Efficacy and Safety of Donidalorsen for Hereditary Angioedema Among Patients in Europe: A Regional Analysis of the OASISplus Study

Thumbnail

D3.441 - Switching to Donidalorsen for Hereditary Angioedema: 1-Year Results From the Phase 3 OASISplus Study

Thumbnail

D3.444 - Efficacy and Safety of Donidalorsen for Patients With Hereditary Angioedema in Europe Who Switched From Prior Long-Term Prophylaxis: Results From the OASISplus Study

Thumbnail

D3.445 - Validation of a Novel Serum-Based Indirect Basophil Activation Test (iBAT) to Evaluate Efficacy of a Pivotal Phase III PQ Grass Immunotherapy Trial

Thumbnail

D3.437 - Impact of benralizumab on fatigue and health-related quality of life in patients with hypereosinophilic syndrome: findings from the NATRON phase 3 trial

Thumbnail

D3.438 - Clinical outcomes with navenibart according to baseline attack rate, body mass index, and age: results of the ALPHA-STAR trial

Thumbnail

D3.439 - Donidalorsen For The Treatment Of Hereditary Angioedema: 1-Year Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.442 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Open-Label Extension Cohort

Thumbnail

D3.443 - Patient-Reported Outcomes With Long-Term Donidalorsen Treatment Among Patients In Europe With Hereditary Angioedema: 1-Year Interim Results From The OASISplus Switch Cohort

Thumbnail

D3.446 - PROTECT Phase I/IIa Clinical Trial Demonstrated Strong Correlation Between Humoral Immune Response and Dose of VLP Peanut in Healthy Participants

Thumbnail

D3.447 - Pre-clinical Toxicology and Immunogenicity Evidence as a Precursor of the Successful Phase I/IIA Study with VLP Peanut